Hussen Jamal, Kandeel Mahmoud, Hemida Maged Gomaa, Al-Mubarak Abdullah I A
Department of Microbiology, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Hofuf, Al-Ahsa 31982, Saudi Arabia.
Pathogens. 2020 Nov 5;9(11):917. doi: 10.3390/pathogens9110917.
Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.
全球为遏制2019冠状病毒病（COVID-19）所做的努力包括研发新型预防性疫苗和有效的治疗方法。使用康复期血浆、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性中和抗体（NAbs）的被动抗体疗法以及单克隆抗体（MAbs）的研发是预防和治疗SARS-CoV-2感染最有前景的策略之一。此外，目前有几种通过多种机制发挥作用的免疫调节抗体正在进行临床试验，这些机制可增强宿主对SARS-CoV-2感染的免疫防御，同时避免免疫系统的有害过度反应。我们的主要目标是介绍在ClinicalTrials.gov上注册的一些临床试验的当前最新进展。我们强调了几种基于SARS-CoV-2抗体的免疫疗法的优点和缺陷。
